Compare Palantir Technologies Inc (PLTR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Tempus AI — how do they compare? Palantir Technologies Inc trades at $168.98 (market cap $409.24B), while Tempus AI trades at $60.43 (market cap $11.67B). The key difference: Palantir Technologies Inc is far larger — about 35.1× Tempus AI's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| PLTR | TEM | |
|---|---|---|
Market Cap | $409.24B | $11.67B |
Sector | Technology | Broad Market / Factor |
52-Week High | $207.18 | $103.25 |
52-Week Low | $107.27 | $41.55 |
Enterprise Value | $400.04B | $12.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir Technologies (PLTR) trades at $170.30, down 2.31% on the day but remains in a strong uptrend with recent earnings beats driving momentum. The stock shows robust fundamentals with 93% revenue growth in Q2 2026 and a 49% net income margin, though valuation metrics remain elevated with a P/E of 145.6. Technical indicators are neutral with support at $168 and resistance at $174, while the recent Nebius partnership strengthens Palantir's sovereign AI positioning.
Palantir's outlook remains positive with strong earnings momentum and strategic AI partnerships, though premium valuation and competitive pressures present risks. The consensus price target of $211.38 suggests 24% upside potential, supported by 50% analyst buy ratings. Key risks include valuation sustainability and compute capacity constraints as demand surges.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
